A general term for a compound that stimulates the pituitary gland to release growth hormone, rather than supplying growth hormone directly. Different growth hormone secretagogues act via different receptors, for example the ghrelin receptor or the GHRH receptor, and this distinction matters for how each is classified and researched. Several peptides in this database, including sermorelin, ipamorelin, CJC-1295 and tesamorelin, are studied specifically because of this shared mechanism, even though their individual evidence bases differ considerably.
Peptides where this matters
-
SermorelinSermorelin acetate
Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.
LimitedNot licensed in the UK -
IpamorelinIPA
Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.
LimitedNot licensed in the UK -
CJC-1295CJC-1295 with DAC
Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.
LimitedNot licensed in the UK -
TesamorelinTH9507
Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.
StrongNot licensed in the UK
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.